occluded delivery system, poor distribution of the therapeutic compound, or backflow around the catheter into the CSF spaces. 23, 24 Monitoring the distribution of therapeutic agents using MRI is valuable for confirming the operation of the infusion system and for accurately measuring the drug's efficacy. Emerging evidence suggests that functional improvement is often linked to drug distribution and drug effectiveness. 1, 7, 8 To improve this technology we evaluated the feasibility of performing MRI monitoring of the MRI contrast agent Gd-DTPA during CED infusion in the brains of NHP. The infusion of this low-molecular-weight contrast agent was imaged during CED to assess its distribution in the brain as a function of infusion volume, infusion rate, and time. In the present study, normal adult rhesus macaques were tested with multiple continuous and chronic CED infusions of Gd-DTPA. MRI was used to monitor catheter patency, volume of distribution of the contrast agent, and kinetics of compound distribution and clearance.
methods experimental animals and design
This study used 6 adult female rhesus monkeys (Macaca mulatta) (age range 8.5-15.5 years, weight 5.0-8.0 kg) obtained from a commercial vendor (Covance). They were individually housed in temperature-and humiditycontrolled rooms, maintained on a 12-hour light/dark cycle. Experienced veterinarians worked closely with skilled laboratory technicians and animal caretakers to monitor the animals on a daily basis. Each animal's home cage activity and behavior were monitored daily to record the use of limbs, tactile/fine motor skills, visual tracking, lacrimation, startle response to noise, and salivation. The protocol for this study was approved by the Institutional Animal Care and Use Committee for the University of Kentucky. All procedures in this study were carried out in compliance with the Institute for Laboratory Animal Research's Guide for the Care and Use of Laboratory Animals.
experimental design
The purpose of this study was to analyze targeted compound delivery into the primate putamen using a catheter designed to promote CED. The MRI contrast agent Gd-DTPA was used so that the infused compound could be tracked by noninvasive neuroimaging. 13 The parameters evaluated were 1) neurological effects from continuous infusion into the putamen, 2) catheter placement, 3) catheter patency, 4) volume of distribution of 2 concentrations of test material, and 5) kinetics of compound distribution and clearance.
Each animal underwent 4 sequential catheter implantations into the putamen. The sequence of events is outlined in Fig. 1 . Catheters were placed first in the right rostral putamen, followed by a left caudal putamen implantation, then third into the right caudal putamen, and finally into the left rostral putamen. Each infusion lasted a total of 14 days. The pump, anchor, and intraparenchymal catheter used are shown in Fig. 2 . The anchor and catheter were removed immediately prior to each new implantation; a single implanted pump was used for all 4 catheters. The multiple surgery strategy permitted repeated testing of catheter patency in the same animal. Anatomical MRI and postmortem tissue evaluation provided important information on how the brain handled multiple implantations to cover extensive target areas.
cage-side clinical observation
Throughout the study, animals were observed cageside at least once daily for abnormalities in motor function manifest in their gait, posture, or general appearance and to monitor water and food consumption and record any vomiting, seizures, or death. The animal's gaze, visual tracking, and pupil diameters were also observed to detect any neurological dysfunction. On observation days after surgery the incision sites were examined for any evidence of complications, such as bleeding, loose sutures, wound dehiscence. Observations were started 3 days prior to surgery and continued through the day of necropsy.
magnetic resonance imaging
MRI scans were performed with a Siemens 3T Tim Trio using a receive-only coil custom built to conform to the animal's head to receive the nuclear magnetic resonance signal. For each imaging session the animal was anesthetized with ketamine and 1%-2% isoflurane, and its head was placed in an MRI-compatible stereotactic frame. During imaging sessions, the animal was kept warm with a combination of water-circulating heating pads and blankets. The animal's physiological state, including respiration, heart rate, peripheral capillary oxygen saturation (SPO 2 ) and exhaled CO 2 , were monitored continuously using a telemetry-operated physiological monitor (PRE-CESS, Invivo Corp.).
surgical planning and patency determination
For surgical planning, we used a 3D MPRAGE sequence with approximate 0.66-mm isotropic resolution (TI 1100 msec, TR 2500 msec, TE 2.5 msec, flip angle 12°, image matrix size 174 × 192 × 115, FOV 116 × 128 × 144 mm) to visualize the putamen and to plan the coordinates of the target site for catheter placement.
catheter replacement and patency determination
Additional MRI scans were obtained approximately 30 minutes as well as 7 and 15 days after catheter implantation. These images were closely examined to measure the accuracy of the catheter placement, catheter patency, and tracer leak-back and to detect any tissue reaction to the placement of the catheter and infusion of the Gd-DTPA. As a result of the infusion of Gd-DTPA the implanted catheter patency was determined from the T1-weighted MR images by checking for high contrast signal surrounding the catheter tip. Structures surrounding the catheter tip were carefully examined by comparing their position and shape on postoperative MR images with those on images obtained before the surgery.
tracer distribution
To estimate the distribution of the tracer we acquired a pair of T1-weighted spoiled gradient recalled acquisition (SPGR) images with the same TR and TE (20 and 3.8 msec, respectively) and spatial resolution but different flip angles. The flip angles (a = 15° and a = 75°) were selected according to the method of Deoni et al. to enable an accurate estimate of T1. 6 From these images, the distribution and clearance of the Gd-DTPA were estimated ( Fig. 3 and 4) .
The volume of infusion (V i ) was determined as the sum of the volumes infused during surgery and the product of the flow rate (Q) and duration until the MR images were acquired. The volume of distribution (V d ) was determined from a calculated relaxation rate R1 = 1/T1 image derived by combining the signal from the pair of 3D gradient recalled echo images. 34 Analysis of these calculated R1 images was conducted using a custom-developed computer program in which a total volume of distribution was derived by defining the area of enhanced R1 on each slice.
The volume of infusion over the 6 time points was modeled using first-order pharmacokinetics. The volume of distribution, V d (t), in the brain was the balance of material infused at a rate Q and eliminated at a rate k el . The This model predicts an equilibrium volume at long times of βQ/k el .
surgical procedures
As described elsewhere, the chronic CED system used in the present study (see Fig. 2 ) is composed of a Medtronic SynchroMed II programmable pump (Model 8610-10), a catheter joining the pump to a cranial anchor (pump catheter), and a cranial catheter. 11 Catheter patency was verified prior to insertion by observing flow from the exit holes. Infusing through the hollow stylet during implantation ensured positive flow out the exit holes, thereby preventing entrapment of blood or other tissue, and thus helped maintain patency. Under sterile field conditions, the cranial catheter was stereotactically placed on the dorsal edge of the putamen using a guide cannula and a 25-gauge hollow stylet, which was fully inserted into the distal catheter and connected to a syringe pump to infuse the Gd-DTPA solution at 1.0 μl/minute. Then the catheter was slowly moved to the target (3 mm above the ventral edge of the putamen). During the first of the 4 surgeries, the pump was subcutaneously implanted in the lateral abdominal region as previously described. 11, 12 The pump was connected to the cranial anchor via the proximal catheter, which was primed with the Gd-DTPA solution prior to attachment to the pump. Once the pump and proximal catheter were implanted (for Sites 2-4, the pump was already implanted), the primed anchor was connected to the distal catheter and a single bolus of between 50-100 μl was delivered at 10 μl/minute. At the end of this bolus the NHP was taken to the MRI area for its postoperative MRI scan.
histology
At the end of the Trial 4 infusion, the brain of each NHP was removed and processed for routine histological evaluation. 12 The entire striatum was cut into 40-μm-thick sections, and every 12th section was stained with hematoxylin and eosin and cresyl violet (Nissl) for gross and microscopic assessment of the tissue damage from the surgical procedures and drug infusion.
results cage-side clinical observations
All NHPs recovered from the surgeries without incident. Throughout the study, no obvious behavioral changes were found in any animal-including loss of consciousness of surroundings, inability to sit upright, impaired use of limbs or tactile/fine motor skills, impaired visual tracking, lacrimation, loss of startle response (to noise), abnormal salivation, or other impairments. All body weights remained uniform for the duration of the study, with an average deviation of 3.4%.
catheter replacement and patency
Catheters were targeted to 2 locations, one directly in front of the other, in the left and right putamen. All catheters but one were positioned inside the putamen as presurgically designed. The exception was a catheter that ended up outside of the boundaries of the putamen (approximately 1 mm in each of the 3 directions) due to accidental loosening of a screw on the head frame during surgery, resulting in movement of the head from the original stereotactic alignment. The mean radial deviation (± SD) of 23 out of 24 placements was 1.5 ± 0.76 mm from the target. A typical target selected and catheter placement in the putamen with acute infusion is demonstrated in 3 dimensions in Fig. 5 . No obvious structural changes, such as compression of the lateral ventricle, were seen when comparing MR images taken before and immediately after the surgical procedure.
patency
Of the 24 catheters, the MR images demonstrated that 1 catheter was blocked permanently, which prevented Gd-DTPA from entering the putamen, and 1 catheter was temporarily blocked, with no Gd-DTPA entering the putamen until after the 7-day 0.1-μl/min infusion (Gd-DTPA was not seen in the Day 7 MRI but appeared in the Day 14MRI). Based on these 2 blockages, the surgical procedure was modified to directly connect the catheter system to an infusing SynchroMed II pump immediately after the needle tip catheter implant and to increase the volume of the bolus from 20 μl (10 μl/min for 2 minutes) to 100 μl (10 μl/min for 10 minutes). These changes were employed for Sites 3 and 4 for a total of 12 infusions.
distribution of gd-dtpa in the brain
In addition to checking catheter patency, we examined the immediate postoperative T1-weighted images for evidence of leak-back along the track of the catheter. We found evidence of minor leak-back, i.e., extending slightly beyond 50% of the catheter length in approximately 25% of the cases. A representative demonstration of the volume of distribution for the 5 time points sampled in the study is illustrated in Fig. 3 . These sagittal MPRAGE images demonstrate the shape of the volume of distribution and the gradual expansion of the distribution with time. The last 2 images, acquired at Days 21 and 28, demonstrate the resolution of the infusion volume as the Gd-DTPA was cleared from the brain. By Day 28 there was little evidence of Gd-DTPA in the brain.
During the first round of surgeries the pumps were filled with a 10-mM solution of Gd-DTPA. After viewing the images obtained immediately after surgery we decided to reduce the concentration of the solution to 5 mM to reduce the intensity of the signal induced by the Gd-DTPA. The volumes derived from NHPs receiving the higher concentration of Gd-DTPA were excluded from further analysis, and all summary statistics were derived only from conditions using the 5-mM Gd-DTPA concentration. The values of V i , V d , and the ratio V d :V i for the various time points are given in Table 1 , which demonstrate how V d increased linearly with V i . Immediately postoperatively, as indicated in Fig. 5 , most of the infusate was contained within the putamen with some Gd-DTPA distributed outside the putamen (Fig. 5C ). At this time point a dose-dependent increase of the V d :V i ratio was found with a greater V d :V i ratio (7.4 ± 3.2 vs 2.1 ± 1.4) seen in the sites with infusion volume of 147 μl versus 62 μl. An incremental increase in V d was observed with an increase of the total V i and total infusion time. The volume of distribution increased more than 2-fold (1936 ± 660 μl vs 818 ± 233 μl) from the acute infusion immediately postsurgery to that after 7 days of continuous chronic infusion at a rate of 0.1 μl/minute. The increase in V d over the 7 days from Day 7 to Day 14 compared with the increase between the immediate postoperative period and Day 7 was 2.9 ± 1.3. This is consistent with V d being proportional to the increase in infusion flow rate from Q = 0.1 μl/minute to 0.3 μl/minute. To better characterize this dependence, the data shown in Fig. 4 were fit to Eq. 2 using a least-squares approach. From this fitting, optimal values of the 3 fitting parameters β, V d (0), and k el were derived as 3.25, 837 ml, and 0.22 L/day. From these values, the data for the best-fit line was derived; it is shown in Fig. 4 as the smooth line passing through the data. From the estimate of k el we derived a value of 3.1 days for the half-life of Gd-DTPA in the brain. Additionally, βQ/k el = 6300 ml is an estimate of the steady-state volume of distribution. From Fig. 4 , this value is seen to be reasonable, as the average volume of distribution at Day 14 is 5250 ml and the curve is clearly still rising.
histological evaluation
As shown in Fig. 6 , the 4 infusion sites were clearly identified and verified to reside in the rostral and caudal putamen. With the exception of the disrupted tissue seen in Trial 4 ( Fig. 6D) , the tissue damage from the catheter placement and the infusion in the other 3 trials was limited ( Fig. 6A-C) . The excessive extracellular fluid is clearly visible in the infused putamen following the Trial 4 infusion in all the cases, but disappeared after the 2-week recovery following Trial 3. In all the animals various amounts of mononuclear inflammatory cells were visible infiltrating the infusion site and the surrounding area. In some cases, small numbers of perivascular inflammatory infiltrates were seen in the infusion zone. Nissl staining showed neuronal loss in the tissue along the catheter track and at the edge of the infusion site, but no detectable decline in neuronal population was observed in other areas.
discussion
All animals tolerated the multiple surgeries for catheter implantation and continuous intraputamenal infusion at various flow rates. No obvious adverse effects on the NHPs, evidenced by cage-side observations, were noticed during the study. Overall outcomes support the contention that it is safe to use the catheter-pump system with chronic CED protocol for intraputamenal delivery of therapeutic agents. In addition, the results of the present study demonstrate that MRI is a valuable tool for visualizing the placement and patency of an implanted catheter and can supply important insights for better understanding of the infused testing agent's distribution in the basal ganglia. 4179 598 ± 380 0.14 ± 0.09 * The measurements for Day 14− were made from MR images acquired prior to the removal of the catheter. The measurements for Day 14+ were made after the removal of the catheter and using MR images acquired immediately after the insertion of a catheter into a new location to start the next trial.
Indeed, 2 blocked catheters were immediately identified, and one of them was confirmed to have reopened 7 days later. The study demonstrated one key advantage of utilizing a programmable pump-that the volume and flow rate can be adjusted based on demand. No blocked catheters were found during the phase of the study when the bolus volume delivered during implantation was increased from 20 to 100 ml. This study used MRI to follow the distribution of the MR contrast agent, Gd-DTPA. The range of tracers used in CED studies is wide, including small-molecular-weight compounds such as Gd-DTPA, 18, 19, 32 dendrimers, 21 iron oxides, 20, 36 nanoparticles, 33 and viruses 5, 32, 33 with attached Gd moieties. The Gd-DTPA tracer is a small-molecularweight contrast agent with the widest FDA approval for use in CNS, body, and head and neck applications in both adults and children. Because our study was designed as a preclinical development we selected a tracer agent with the greatest likelihood of being approved for use as an indicator of patency.
The method of estimating the volume of distribution was made by using a calculated T1 image derived from a pair of gradient recalled echo images acquired at the same locations. This method enables an accurate estimate of the volume of drug delivered and is less dependent upon an arbitrary threshold in image intensity or selection of the concentration of the Gd-DTPA.
2 T1-weighted images such as are produced by MPRAGE sequences can still be analyzed but only after filtering to remove the spatial variation in signal intensity. The method is also likely to be more indicative of the distribution of an infused compound than is T2, which would demonstrate primarily the development of edema. 15 The ratio of V d :V i measured immediately after surgery was 5.56 ± 1.6, which then decreased to 1.68 ± 0.57 after 7 days of continuous infusion delivered an additional 1008 ml. The ratio of V d :V i declined further to 1.34 ± 0.35 after 14 days, with a total of 4179 ml infused. The ratio of V d :V i for the acute infusion found in this study is consistent with that found for acute infusion of a similar-sized MR contrast agent into the putamen of NHP. 38 It is also consistent with measurements of a much larger molecule, 123 I-labeled human serum albumin, which was infused into malignant glioma in patients. 25 In that study the V d :V i ratio after 48 hours was between 1.07 and 2.96, depending upon the isodose level used to define the distribution. Despite the consistency seen among these measurements, we expect that many factors-including the tissue in which the catheter is placed, the infusion rate, and the physical and chemical characteristics of the molecule infused (such as its molecular weight and its charge)-will affect distribution.
The results of the present study demonstrate that an incremental increase in the V d accompanied an increase of the total V i and the total infusion time during the first 7 days with continuous infusion at 0.1 ml/minute. Then, over the next 7 days with the flow rate increased to 0.3 ml/ minute, the average V d increased continuously, reaching a value 2.8 times higher than the value at Day 0. Our results differ from those of a previous NHP study in which prolonged (up to 10 days) infusion of Gd+topotecan did not lead to a constant expansion of V d , but rather maintained a constant volume. In the previous study, an open-tip catheter delivered a different material (Gd+topotecan) at a much higher flow rate of 0.486 ml/minute into the brains of a different species (pigs). 29 The results from this study suggest that different settings could lead to significant differences in clearance rates.
Theoretically, the bulk flow should follow the path of least resistance. Expansion outside the putamen will occur if the catheter tip is placed too close to white matter fiber tracks such as the corpus callosum. For example, in a GDNF study, backflow was only seen along the catheter tract passing the corpus callosum or very close to the internal capsule. 2 Yin and colleagues also concluded that good distribution of infusates by CED depends very much on cannula design, precise cannula placement, and infusion rates. 37 The most significant determinant of putamenal containment was the length of the cannula tip and the distance of the cannula step to the corpus callosum. 37 In the present study, we carefully selected the target area to be two-thirds down from the dorsal edge of the putamen; this ensured that the stepped portion of the needle tip was at least 2 mm into the putamen to avoid the infusate flowing back along the catheter.
Infusion rates could be another critical factor for successful induction of convection into the brain. The infused solution can leak out from the cannula track, resulting in a loss of infusion pressure, if the infusion rate is greater than a few microliters per minute. 3 In the present study, we found that the tracer was contained inside the putamen at rates of 0.1 and 0.3 ml/min, and the flow rate at 0.3 ml/min was used without any occurrence of backflow. Similar results were also seen in our previous studies of GDNF. 1, 11, 12 The histological findings indicated that the NHP brain can tolerate multiple surgical implants of the catheter as well as handle the flow rate and volume of the infusion through the putamenal catheter without observed behavioral change. Those results suggest that the flow rate could be used to achieve maximal distribution with minimal damage to the brain tissue.
Finally, MRI allowed the accurate determination of the volume of infusion at the 5 time points used in this study. By calculating the relaxation rate R1, we were able to derive a more accurate estimate of the volume of infusion than could be derived from image enhancement on MPRAGE images alone. From these estimates it is possible to characterize the kinetics of the infusion and clearance, which enables better prediction of the volume of distribution for flow rates and times outside those used in the study. Additionally, because the V d :V i ratio declines with increasing V i , the steady-state volume of distribution may become a more appropriate measure for chronic CED infusion with a long infusion period.
conclusions
This work first demonstrated 1) the ability to accurately place a chronically implanted catheter in a predetermined target that is deep in the brain; 2) the use of MRI to visualize a MRI-visible tracer to follow the evolution of the infusion volume over time; and 3) the ability to safely deliver compounds in a chronic and continuous fashion in a large brain. The study supplied more insights into understanding fluid delivery and pharmacokinetic performance of a system used for chronic CED. The results suggest that the delivery system could be safe and effective in delivering therapeutic compounds in the large primate brain and could be translated into a clinical setting with some modifications for treatments of neurological disorders like Parkinson's disease and Huntington's disease. 
